

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/786,361	07/26/2001	George M. Grass	109904-00015	6311
Arent Fox Kint	7590 01/22/2007	EXAMINER		
Plotkin & Kahr		BRUSCA, JOHN S		
Suite 600 1050 Connecticut Avenue NW Washington, DC 20036-5339			ART UNIT	PAPER NUMBER
			1631	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MO	NTHS	01/22/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

一件

	Application No.	Applicant(s)				
	09/786,361	GRASS ET AL.				
Office Action Summary	Examiner	Art Unit				
	John S. Brusca	1631				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	66(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>30 June 2006</u> .						
2a) This action is FINAL . 2b) ☐ This	2a) This action is FINAL . 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims		•				
4)⊠ Claim(s) <u>1-52,80-121 and 137-231</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-52,80-121 and 137-231</u> is/are reject	ed.					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) 6) Other:						

Application/Control Number: 09/786,361 Page 2

Art Unit: 1631

DETAILED ACTION

Withdrawal of Finality and Reopening of Prosecution

1. As noted in the interview summary of 26 October 2006, the finality of the Office action mailed 28 July 2006 is withdrawn and prosecution is reopened to apply a new grounds of rejection under 35 U.S.C. 101. The applicants have not filed an after final amendment subsequent to the mailing of the final Office action on 28 July 2006.

Oath/Declaration

2. The application file does not contain a copy of the Rule 63 Declaration filed on 26 June 2001. The application file contains a cover letter stating that a declaration was being filed, and the application was subsequently approved for entry as a national state application under 35 U.S.C. 371 on 27 July 2001, indicative of receipt by the office of the declaration. The applicants are requested to provide a copy of the declaration to complete the application file.

Claim Rejections - 35 USC § 101

- 3. 35 U.S.C. 101 reads as follows:
 - Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.
- 4. Claims 1-53, 80-121, and 137-231 are rejected under 35 U.S.C. 101 because the claims do not comprise a tangible result.

Claims 1-53, 80-121, and 137-231 are drawn to a process and computers and programs for executing the process. A statutory process must include a step of a physical transformation, or produce a useful, concrete, and tangible result (State Street Bank & Trust Co. v. Signature

Art Unit: 1631

Financial Group Inc. CAFC 47 USPQ2d 1596 (1998), AT&T Corp. v. Excel Communications
Inc. (CAFC 50 USPQ2d 1447 (1999)). In the instant claims, there is no step of physical transformation, thus the Examiner must determine if the instant claims include a useful, concrete, and tangible result.

As noted in State Street Bank & Trust Co. v. Signature Financial Group Inc. CAFC 47 USPQ2d 1596 (1998) below, the statutory category of the claimed subject matter is not relevant to a determination of whether the claimed subject matter produces a useful, concrete, and tangible result:

The question of whether a claim encompasses statutory subject matter should not focus on which of the four categories of subject matter a claim is directed to 9-- process, machine, manufacture, or composition of matter-but rather on the essential characteristics of the subject matter, in particular, its practical utility. Section 101 specifies that statutory subject matter must also satisfy the other "conditions and requirements" of Title 35, including novelty, nonobviousness, and adequacy of disclosure and notice. See In re Warmerdam, 33 F.3d 1354, 1359, 31 USPQ2d 1754, 1757-58 (Fed. Cir. 1994). For purpose of our analysis, as noted above, claim 1 is directed to a machine programmed with the Hub and Spoke software and admittedly produces a "useful, concrete, and tangible result." Alappat, 33 F.3d at 1544, 31 USPQ2d at 1557. This renders it statutory subject matter, even if the useful result is expressed in numbers, such as price, profit, percentage, cost, or loss.

In determining if the claimed subject matter produces a useful, concrete, and tangible result, the Examiner must determine each standard individually. For a claim to be "useful," the claim must produce a result that is specific, and substantial. For a claim to be "concrete," the process must have a result that is reproducible. For a claim to be "tangible," the process must produce a real world result. Furthermore, the claim must be limited only to statutory embodiments.

Application/Control Number: 09/786,361 Page 4

Art Unit: 1631

Claims 1-53, 80-121, and 137-231 do not produce a tangible result. A tangible result requires that the claim must set forth a practical application to produce a real-world result. This rejection could be overcome by amendment of the claims to recite that a result of the method is outputted to a display or a memory or another computer on a network, or to a user, or by including a physical transformation.

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1631

7. Claims 1-53, 80-121, and 137-231 rejected under 35 U.S.C. 103(a) as being unpatentable over Grass (reference BW in the Information Disclosure Statement filed 17 July 2001) in view of Gex-Fabry et al. (reference BT in the Information Disclosure Statement filed 17 July 2001).

The claims are drawn to a method of using a pharmacokinetic model to predict a pharmacokinetic property of a compound in a second anatomical location by use of a pharmacokinetic property of a test compound in a first anatomical location. In some embodiments parameters such as a selected adjustment parameter or a regional correlation parameter are refined by use of data from a plurality of compounds. In some embodiments the claims are drawn to computers or programs that execute the method. In some embodiments the model uses in vitro data, log functions, programs and computers using if..then statements, models comprising absorption models in the gastrointestinal tract, differential equations, and models that comprise properties of two different species of animal or tissues or cells.

Grass et al. shows in the abstract and throughout pharmacokinetic models that predict behavior of compounds in animals. Grass shows use of in vivo, in situ, and in vitro pharmacokinetic data of compounds on pages 202-205, models with log functions on page 205, computers and programs that execute the method on page 207, programs with if..then statements on page 207 models of absorption in multiple segments of the gastrointestinal tract on page 207 and throughout, models using differential equations on page 208, models that compare behavior of different species of animals on pages 209-211, and models that use behavior of tissue and in vitro cells on page 209-211. Grass shows in figures 19 and 20 that the models provide accurate predictions of absorption of two different compounds in the gastrointestinal tract. Grass et al.

Application/Control Number: 09/786,361 Page 6

Art Unit: 1631

does not explicitly show fitting of pharmacokinetic data of multiple compounds to derive parameters for use in the model.

Gex-Fabry et al. reviews computer models of pharmacokinetic behavior of compounds in anatomical sites. Gex-Fabry et al. shows on page 513 and beyond the use of data to refine parameter values that are used in computer pharmacokinetic models.

It would have been obvious to a person of ordinary skill in the art at the time the invention was made to modify the method and computer models of Grass et al. by refining the parameters used in the model by use of data from a plurality of compounds because Gex-Fabry et al. shows such refinement is useful to obtain more accurate parameters.

Conclusion

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to John S. Brusca whose telephone number is 571 272-0714. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571 272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

John S. Brusca 17 January 2007

Primary Examiner

Art Unit 1631